Biosimilar allergy drug trial halted after just one volunteer
NCT ID NCT04361812
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial aimed to see if a new biosimilar drug called HS632 works like the approved allergy drug Omalizumab (Xolair) in healthy volunteers. The study planned to compare how the body absorbs and handles each drug after a single injection. However, the trial was terminated early with only one participant enrolled, so no meaningful results were obtained.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS632 (a biosimilar of omalizumab)
What this could lead to
If successful, this could support the development of a more affordable version of omalizumab for allergic conditions.
What could go wrong
This was a very early Phase 1 study in only healthy people, not patients. It was terminated early with just one participant, so no conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SIMILARITY OF PHARMACOKINETICS AND SAFETY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Peng
Shanghai, Shanghai Municipality, 200040, China